Epstein–Barr virus IgG antibody array LMP1/2 EBNA protein Introduction Epstein–Barr virus (EBV) is a common pathogen that is generally acquired during early childhood, with nearly all adults harbouring evidence of prior EBV exposure in the form of systemic immunoglobulin G (IgG) antibodies agains...
AB Rickinson, M Rowe, I Hart, QY Yao, LE Henderson, H Rabin, MA Epstein T cell-mediated regression of “spontaneous” and of Epstein-Barr virus-induced B cell transformation in vitro: Studies with cyclosporin A. Cell Immunol, 87 (1984), p. 646 View PDFView articleView in ScopusGoogle...
In Epstein-Barr virus (EBV) infection, IgG- and IgM-antibodies to viral capsid antigen (VCA) and IgG-antibodies to Epstein-Barr nuclear antigen 1 (EBNA-1) can occur simultaneously both in late primary infection and during subclinical viral reactivation in immunocompetent persons, and the differen...
Epstein-Barr virus infection of HIV-seropositive individuals is transiently suppressed by high-dose acyclovir treatment ADDS, 7 (1993), p. 1337 CrossrefView in ScopusGoogle Scholar 23 Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB The Epstein-Barr virus-host balance in acute infectious monon...
Adoptive transfer of CTLs targeting EBNA1, LMP1, and LMP2 has shown some level of anti-tumor responses in some NPC patients.7,22 In therapeutic immunization approaches, different approaches displaying different EBV antigens have been studied in clinical and preclinical studies. These include ...